Measurable changes in Aβ and tau are preceded by BBB breakdown, detection of which may facilitate earlier diagnosis of AD and implementation of disease-modifying therapeutics (Sweeney et al., 2018, 2019). Here, MAPT is linked to Alzheimer disease.